Amiot Aurelien, Jooste Valerie, Gagniere Charlotte, Lévy Michaël, Copie-Bergman Christiane, Dupuis Jehan, Le Baleur Yann, Belhadj Karim, Sobhani Iradj, Haioun Corinne, Bouvier Anne-Marie, Delchier Jean-Charles
a Department of Gastroenterology , Groupe Hospitalier Henri Mondor-Albert Chennevier, APHP , Creteil , France.
b Faculté de Médecine , Université Paris Est-Creteil (UPEC) , Creteil , France.
Leuk Lymphoma. 2017 Sep;58(9):1-11. doi: 10.1080/10428194.2017.1283033. Epub 2017 Jan 31.
To assess the risk of second primary malignancy (SPM) in patients with gastric mucosa-associated lymphoid tissue (MALT) Lymphoma (GML), we included 175 patients with GML in the present study. The incidence of SPM in the general population, used for reference, was determined from the French network of cancer registries. During the 1442.9 patient-years of follow-up, 29 patients were diagnosed with incident SPM, including five patients diagnosed with gastric cancer (20.1/1000 patient-years). An increased incidence of SPM was observed in patients with GML (standardized incidence ratios [SIR]: 1.71 [1.14-2.45]) compared to the general French population especially for gastric cancer (SIR: 16.1 [5.19-37.56]). This elevated risk of SPM was significantly increased only in patients treated with immuno/chemotherapy but not in patients treated with Helicobacter pylori eradication alone. Long-term follow-up of patients with GML is mandatory even in patients who have achieved complete remission.
为评估胃黏膜相关淋巴组织（MALT）淋巴瘤（GML）患者发生第二原发性恶性肿瘤（SPM）的风险，我们在本研究中纳入了175例GML患者。用于参考的一般人群中SPM的发病率是根据法国癌症登记网络确定的。在1442.9患者年的随访期间，29例患者被诊断为新发SPM，其中5例被诊断为胃癌（20.1/1000患者年）。与法国普通人群相比，GML患者中观察到SPM发病率增加（标准化发病率比[SIR]：1.71[1.14 - 2.45]），尤其是胃癌（SIR：16.1[5.19 - 37.56]）。仅在接受免疫/化疗的患者中，SPM的这种升高风险显著增加，而在仅接受幽门螺杆菌根除治疗的患者中则未增加。即使在已实现完全缓解的患者中，对GML患者进行长期随访也是必要的。
